Tag Archives: Johnson & Johnson
New Prostate Cancer Drug Approved by FDA
Good news for patients with metastatic prostate cancer. The FDA (US Food and Drug Administration) has approved Johnson & Johnson’s Zytiga (abiraterone) in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy. Abiraterone … Continue reading →
Posted in Cancer, Prostate cancer
|
Tagged abiraterone, cabazitaxel, FDA, Jevtana, Johnson & Johnson, metastatic, Prostate cancer, Provenge, sipuleucel-T, Zytiga
|
1 Comment